nasdaq:imnp
|
940900
|
Mar 24th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 24th, 2024 01:34AM
|
Mar 24th, 2024 01:34AM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 23rd, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 22nd, 2024 11:46PM
|
Mar 23rd, 2024 06:55PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 22nd, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 21st, 2024 11:36PM
|
Mar 22nd, 2024 06:44PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 21st, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 20th, 2024 11:49PM
|
Mar 21st, 2024 05:27PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 20th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 20th, 2024 12:20AM
|
Mar 20th, 2024 07:28PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 19th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 18th, 2024 11:24PM
|
Mar 19th, 2024 06:00PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 18th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 17th, 2024 11:46PM
|
Mar 18th, 2024 07:12PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 17th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 17th, 2024 01:14AM
|
Mar 17th, 2024 01:14AM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 16th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 15th, 2024 11:16PM
|
Mar 16th, 2024 07:00PM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:imnp
|
940900
|
Mar 15th, 2024 12:00AM
|
Immune Pharmaceuticals Inc.
|
1.6K
|
6.00
|
Open
|
|
Mar 15th, 2024 12:37AM
|
Mar 15th, 2024 08:49AM
|
Immune Pharmaceuticals Inc. (OTCQB: IMNP) is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Immune’s lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, Immune is conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other indications, including atopic dermatitis, asthma, and other diseases. Immune is also developing NanoCyclo, a topical formulation of cyclosporine, for atopic dermatitis and psoriasis, which is currently in late-stage preclinical testing.
|
Open
|
Pharmaceuticals, Nanomabs, Monoclonal Antibodies, biotechnology, bullous pemphigoid , and biopharmaceuticals
|
Open
|
1 Bridge Plaza N
|
Fort Lee
|
New Jersey
|
US
|
07024
|
|
Immune Pharmaceuticals
|
|
Pharmaceuticals & Biotechnology
|